Community Acquired Pneumonia Pipeline Review 2021

Report Code: PMI460721 | Publish Date: February 2021 | No. of Pages: 132

Community Acquired Pneumonia Pipeline Review 2021 Overview

Community-acquired pneumonia (CAP) is a foremost cause of mortality and morbidity worldwide. Community-acquired pneumonia is referred to as pneumonia which is acquired outside the hospital. The most commonly identified pathogens are Haemophilus influenzae, Streptococcus pneumoniae, viruses, and atypical bacteria (i.e., Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella species). The signs and symptoms are cough, fever, sputum production, dyspnea, tachypnea, pleuritic chest pain, and tachycardia.

Diagnosis involves clinical presentation and chest x-ray. Treatment basically involves empirically selected antibiotics. Prognosis is brilliant for healthy relatively or young patients, but many pneumonias, particularly when caused by S. pneumoniae, Staphylococcus aureus, Legionella, or influenza virus, are serious or even fatal in sicker, older patients.

Combioxin SA is presently running two parallel programs depending on an innovative technology planned to fight severe bacterial (CAL02) and viral (CX-Viro) infections. CAL02 is a phase 2-stage drug that has successfully been tested in ICU patients with severe community-acquired pneumonia. CX-Viro targets the fundamental first step of COVID-19 infection: viral entry into host cells. The drug is ready for clinical trial in COVID-19 patients.

Approximately 70% of pipeline drugs for community acquired pneumonia are in phase 3 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent community acquired pneumonia.

Report Description

The report on Community Acquired Pneumonia- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Community Acquired Pneumonia. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

  • Assessment of pipeline products based on various stages of devolvement.
  • Provides an overview of the global therapeutic landscape of Community Acquired Pneumonia (Infectious Disease).
  • Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
  • The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
  • Latest news, articles, press-release, and related conferences

Community Acquired Pneumonia Pipeline Review 2021 Key Issues Addressed

  • Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
  • Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
  • Build strategic initiatives by understanding the focus areas of leading companies
  • Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Community Acquired Pneumonia Pipeline Review 2021 Table of Contents


  1. Introduction
  • Objectives of the Study
  • Definition
  • Report Overview
  • Community Acquired Pneumonia Overview
  1. Executive Summary
  2. Community Acquired Pneumonia: Pipeline Assessment
  • Company Overview
  • Product Description
  • Status
  • Phase
  • Study Design
  • Route of Administration
  • Indication       
  • Condition        
  • NCT Number              
  • Sponsor          
  • Collaborator   
  • Brief Title         
  • Study Start Date         
  • Study completion (Estimated/Actual)
  • Study Completion Date
  • Enrollment     
  • Research Location (Listed Location Countries)
  1. Community Acquired Pneumonia: Analysis on Dormant & Discontinued Pipeline Candidates
  • Overview
  • Product Description
  • Reason for Discontinuation
  1. Community Acquired Pneumonia: Additional Key Insights
  • Epidemiology Overview: Community Acquired Pneumonia
  1. Community Acquired Pneumonia: Press Releases, Latest News and Conference Details


  • Table of Content is tentative and subject to change as the research progresses
  • The drug candidates are included as examples in the pipeline when this ToC was designed and their status might have changed since then.